Safety and Tolerability of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart (NovoLog) When Used in Insulin Pumps in Adults with Type 1 Diabetes: A Randomized, Open-Label Clinical Trial.

Find People
Find Research
Overview
Tutorials
FAQs
Edit My PROFILE
Login to PROFILES

Contact Us
If you have any questions or feedback please contact us.

Safety and Tolerability of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart (NovoLog) When Used in Insulin Pumps in Adults with Type 1 Diabetes: A Randomized, Open-Label Clinical Trial.

Thrasher J, Polsky S, Hovsepian L, Nowotny I, Pierre S, Bois De Fer B, Bhargava A, Mukherjee B, Garg SK. Safety and Tolerability of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart (NovoLog) When Used in Insulin Pumps in Adults with Type 1 Diabetes: A Randomized, Open-Label Clinical Trial. Diabetes Technol Ther. 2020 09; 22(9):666-673.

View in: PubMed

subject areas

Adult
Aged
Biosimilar Pharmaceuticals
Blood Glucose
Cross-Over Studies
Diabetes Mellitus, Type 1
Female
Humans
Hypoglycemic Agents
Insulin Aspart
Insulin Infusion Systems
Male
Middle Aged

authors with profiles

Sarit Polsky
Satish K Garg

Contact Us
CCTSI
About CCTSI
CCTSI Affiliated Institutions
National CTSA Consortium